H.C. Wainwrigh on Kalvista Pharmaceuticals Inc (KALV): FY25 Ekterly revs show strong demand for HAE patients
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $37.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV)The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)